Karyopharm Therapeutics (KPTI) Net Cash Flow (2012 - 2025)

Karyopharm Therapeutics has reported Net Cash Flow for 14 years, with the latest figure at $22.9 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow rose 321.27% year-over-year to $22.9 million; the trailing twelve-month figure through Dec 2025 stood at -$2.3 million (up 92.66% YoY), and the FY2025 full-year result was -$1.9 million, down 120.17% from the prior year.
• Net Cash Flow for Q4 2025 stood at $22.9 million, up from -$1.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $63.7 million in Q4 2022, with the low at -$70.4 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$3.4 million across 5 years, with a median of -$3.1 million in 2021.
• Annual changes were most pronounced in 2021 — Net Cash Flow soared 1107.8% — and 2022, when it sank 4458.21%.
• Karyopharm Therapeutics' Net Cash Flow stood at $57.1 million in 2021, then climbed by 11.48% to $63.7 million in 2022, then tumbled by 86.62% to $8.5 million in 2023, then plunged by 221.25% to -$10.3 million in 2024, then surged by 321.27% to $22.9 million in 2025.
• The last three Net Cash Flow figures came in at $22.9 million (Q4 2025), -$1.1 million (Q3 2025), and -$412000.0 (Q2 2025), per Business Quant data.